Vetter Development Services USA, Inc.

Primary objective: To demonstrate the superiority of Anifrolumab over placebo in moderate improvement of disease activity at week 52 Key secondary objectives: 1. To demonstrate the superiority of Anifrolumab over placebo in muscle improvement at week 52 2. To demonstrate the superiority of Anifrolumab over placebo in OCS dose reduction at week 52 3. To demonstrate the superiority of Anifrolumab over placebo in moderate improvement of disease activity in PM subjects at week 52 4. To demonstrate the superiority of Anifrolumab over placebo in moderate improvement of disease activity in DM subjects at week 52 5. To demonstrate the superiority of Anifrolumab over placebo in improvement of skin disease activity at week 8 Secondary objectives: 1. To evaluate the effectiveness of Anifrolumab compared with placebo in disease activity at week 52

Part A: Dose escalation: Evaluate the safety and tolerability of AZD0486 in subjects with Ph(+) or Ph(-) R/R B-ALL aged 16-80 years (inclusive). Part B: Dose optimization: Evaluate the preliminary efficacy of AZD0486 according to NCCN efficacy criteria; Evaluate the safety and tolerability of AZD0486 in subjects with R/R Ph(-) B-ALL aged 12-80 years (inclusive). Part C: Efficacy extension: Evaluate the efficacy of AZD0486 according to NCCN efficacy criteria.

To evaluate the effect of lepodisiran on major adverse cardiovascular events in adults with elevated lipoprotein(a) levels